OrbiMed’s Organon & Co OGN Stock Holding History

OrbiMed’s Portfolio OGN Stock Details OGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-166,939	Closed	-$5.05M	–	182
2021 Q2	$5.05M	Buy	+166,939	New	+$5.5M	0.05%	148

Other funds holding OGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OrbiMed's OGN Position: Q3 2021 in Review

OrbiMed sold out of Organon & Co (OGN) in Q3 2021, closing a stake of 166,939 shares — an estimated $5.05M sold.

OrbiMed first reported a position in OGN in Q2 2021 and held it in 1 quarter. The position peaked at $5.05M in Q2 2021. 928 funds tracked by Wall St. Rank hold OGN as of Q3 2021.

OrbiMed reported no remaining Organon & Co position as of Q3 2021 after selling out during the quarter.
OrbiMed sold 166,939 Organon & Co shares in Q3 2021, an estimated $5.05M.
OrbiMed first reported a position in Organon & Co in Q2 2021 and held it in 1 quarter.
OrbiMed's Organon & Co position peaked at $5.05M in Q2 2021.
928 funds tracked by Wall St. Rank held Organon & Co as of Q3 2021.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.